Publications
Publications 1126 - 1150 de 33557
| Titre | DOI |
|---|---|
|
A Performance Metric for Co-Optimization of Day-Ahead Dispatch and Reserves in Electric Microgrids M. Panwar; R. Hovsapian; R. Roche; S. Suryanarayanan 2019 |
|
|
A Performance Metric for Co-Optimization of Day-Ahead Dispatch and Reserves in Electric Microgrids M. Panwar; R. Hovsapian; R. Roche; S. Suryanarayanan 2019 |
|
|
A permutation code preserving a double Eulerian bistatistic J.L. Bari; V. Vajnovszki 2017 |
10.1016/j.dam.2017.02.014 |
|
A persistent acrocyanosis in a 55 year-old woman S. Humbert; J. Razanamahery; C. Payet-Revest; N. Meaux-Ruault; H. Gil; N. Magy-Bertrand; J. London 2019 |
10.1016/j.revmed.2019.05.002 |
|
A Personal LPWAN Remote Monitoring System G.Bou Tayeh; C. Guyeux; A. Makhoul; J.M. Bahi; S. Freidig 2021 |
10.1109/IWCMC51323.2021.9498794 |
|
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia L. Fenwarth; X. Thomas; S. de Botton; N. Duployez; J.H. Bourhis; A. Lesieur; G. Fortin; P.A. Meslin; I. Yakoub-Agha; P. Sujobert; P.Y. Dumas; C. Recher; D. Lebon; C. Berthon; M. Michallet; A. Pigneux; S. Nguyen; S. Chantepie; N. Vey; E. Raffoux; K. Celli-Lebras; C. Gardin; J. Lambert; J.V. Malfuson; D. Caillot; S. Maury; B. Ducourneau; P. Turlure; E. Lemasle; C. Pautas; S. Chevret; C. Terre; N. Boissel; G. Socie; H. Dombret; C. Preudhomme; R. Itzykson 2021 |
10.1182/blood.2020005524 |
|
A Pharmacoepidemiological study of intravitreal drug consumption in the first 12 months of treatment. The EPIdemiology and SAFEty collaboration V. Daien; C.P.Creuzot Garcher; M.N. Delyfer; A.M. Bron; M.C. Gillies; S. Lacombe; L. Papinaud; D. Cholley; C. Domerg; A. Cougnard-Gregoire; C. Quantin; M. Villain; J.Pierre Daures; C. Delcourt; J.F. Korobelnik 2017 |
|
|
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma: The GOELAMS LCP 99 trial G. Olivier; A. Clavert; L. Lacotte-Thierry; M. Gardembas; M. Escoffre-Barbe; A. Brion; I. Cumin; E. Legouffe; P. Solal-Celigny; M. Chabin; P. Ingrand; P. Colombat; V. Delwail 2014 |
10.1002/ajh.23812 |
|
A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results R.S. Herbst; J.C. Bendell; N. Isambert; E. Calvo; R. Santana-Davila; P. Cassier; J.Luis Perez-Gracia; J. Yang; J. Rege; D. Ferry; G. Mi; I. Chau 2016 |
10.1200/JCO.2016.34.15_suppl.3056 |
|
A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study Q. Jacquinot; N. Meneveau; M. Chatot; F. Bonnetain; B. Degano; M. Bouhaddi; G. Dumoulin; D. Vernerey; X. Pivot; F. Mougin 2017 |
10.1186/s12885-017-3420-4 |
|
A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+unresectable locally advanced or metastatic breast carcinoma (MBC) G. Curigliano; S. Loibl; V. Mueller; X. Pivot; A. Wardley; D. Cameron 2016 |
10.1093/annonc/mdw365.91 |
|
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma R. Gressin; N. Daguindau; A. Tempescul; A. Moreau; S. Carras; E. Tchernonog; A. Schmitt; R. Houot; C. Dartigeas; J.Michel Pignon; S. Corm; A. Banos; C. Mounier; J. Dupuis; M. Macro; J. Fleury; F. Jardin; C. Sarkozy; G. Damaj; P. Feugier; L.Matthieu Fornecker; C. Chabrot; V. Dorvaux; K. Bouadallah; S. Amorin; R. Garidi; L. Voillat; B. Joly; P.Solal Celigny; N. Morineau; M.Pierre Moles; H. Zerazhi; J. Fontan; Y. Arkam; M. Alexis; V. Delwail; J.Pierre Vilque; L. Ysebaert; S. Le Gouill; M.B. Callanan; L.Study Assoc 2019 |
10.3324/haematol.2018.191429 |
|
A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) N. Kalakonda; F. Cavallo; G. Follows; A. Goy; J.S.P. Vermaat; O. Casasnovas; O. Lavee; M. Maerevoet; J. Zijlstra; S. Bakhshi; R. Bouabdallah; S. Choquet; R. Gurion; B. Hill; U. Jaeger; J.M. Sancho; M. Schuster; C. Thieblemont; F. De la Cruz; M. Egyed; S. Mishra; F. Offner; T. Vassilakopoulos; K. Warzocha; D. McCarthy; X. Ma; K. Corona; J.R. Saint-Martin; A. Joshi; J. Shah; E. Van Den Neste; M. Canales 2019 |
10.1016/j.clml.2019.07.153 |
|
A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1. K. Fizazi; X. Maldonado; S. Foulon; G. Roubaud; R.S. McDermott; A. Flechon; B.F. Tombal; S. Supiot; D.R. Berthold; P. Ronchin; G. Kacso; G. Gravis; F. Calabro; J.Francois Berdah; A. Hasbini; M. Silva; A. Thiery-Vuillemin; I. Rieger; M.Laure Tanguy; A. Bossi 2021 |
10.1200/JCO.2021.39.15_suppl.5000 |
|
A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma G. Truc; V. Bernier; C. Mirjolet; C. Dalban; F. Mazoyer; F. Bonnetain; N. Blanchard; E. Lagneau; P. Maingon; G. Noel 2016 |
10.1016/j.canrad.2015.12.005 |
|
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study) P. Fumoleau; K.M. Koch; E. Brain; F. Lokiec; K. Rezai; A. Awada; L. Hayward; G. Werutsky; J. Bogaerts; S. Marreaud; F. Cardoso 2014 |
10.1016/j.breast.2014.07.003 |
|
A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee) B. Nelken; H. Cave; G. Leverger; C. Galambrun; G. Plat; C. Schmitt; C. Thomas; C. Verite; B. Brethon; V. Gandemer; Y. Bertrand; A. Baruchel; P. Rohrlich 2016 |
10.1002/pbc.25751 |
|
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study V. Dieras; T. Bachelot; M. Campone; N. Isambert; F. Joly; C. Le Tourneau; P. Cassier; E. Bompas; P. Fumoleau; S. Noal; C. Orsini; M. Jimenez; D.Charlotte Imbs; E. Chatelut 2016 |
10.1007/s40487-016-0027-x |
|
A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors. N. Isambert; E. Elez; S. Zanetta; I. Matos; S. Nazabadioko; W. Xue; P. Carriere; J. Tabernero 2018 |
10.1200/JCO.2018.36.15_suppl.e24013 |
|
A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. N.Guastad Daver; P. Montesinos; D.J. DeAngelo; E.S. Wang; E. Todisco; C. Tarella; G. Martinelli; H.Paul Erba; E. Deconinck; K.L. Sweet; R.B. Walter; M.Yair Levy; N. Pemmaraju; A.A. Lane; D. Rizzieri; M. Konopleva; C.Mortimer Sloss; J. Wang; K.E. Malcolm; P.A. Zweidler-McKay 2020 |
|
|
A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. N.Guastad Daver; P. Montesinos; D.J. DeAngelo; E.S. Wang; E. Todisco; C. Tarella; G. Martinelli; H.Paul Erba; E. Deconinck; K.L. Sweet; R.B. Walter; M.Yair Levy; N. Pemmaraju; A.A. Lane; D. Rizzieri; M. Konopleva; C.Mortimer Sloss; J. Wang; K.E. Malcolm; P.A. Zweidler-McKay 2020 |
|
|
A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy F. Morschhauser; G.Andre Salles; R.O. Casasnovas; P. Feugier; K. Bouabdallah; G. Cartron; R. Bouabdallah; E. Nicolas-Virelizier; M. Maerevoet; S. Snauwaert; C. Fruchart; S.L.E. Gouill; C. Molucon-Chabrot; C. Delette; L. Molina; H. Tilly; C. Thieblemont; E. Van Den Neste; F. Bijou; B. Fabiani; C. Haioun; R. Houot 2018 |
10.1182/blood-2018-99-112805 |
|
A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma F. Morschhauser; G. Cartron; G.A. Salles; F. Bijou; C. Fruchart; K. Bouabdallah; P. Feugier; S. Le Gouill; H. Tilly; C. Molucon-Chabrot; M. Maerevoet; R.O. Casasnovas; E.W. Van den Neste; P. Zachee; K. Van Eygen; A. Van Hoof; C. Bonnet; C. Haioun; M. Andre; L. Xerri; R. Houot 2016 |
10.1182/blood.V128.22.4202.4202 |
|
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study) P. Pautier; N. Penel; I. Ray-Coquard; A. Italiano; E. Bompas; C. Delcambre; J.O. Bay; F. Bertucci; J. Delaye; C. Chevreau; D. Cupissol; L. Bozec; J.C. Eymard; E. Saada; N. Isambert; C. Guillemet; M. Rios; S. Piperno-Neumann; G. Chenuc; F. Duffaud 2020 |
10.1016/j.ejca.2019.10.028 |
|
A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 ``PembroRad'' trial. X.Shan Sun; C. Sire; Y. Tao; L. Martin; M. Alfonsi; J.Briac Prevost; M. Rives; C. Lafond; J.M. Tourani; J. Biau; L. Geoffrois; A. Coutte; X. Liem; E. Vauleon; F. Drouet; J.F. Ramee; G. Waksi; L. Sinigaglia; A. Auperin; J. Bourhis 2018 |
10.1200/JCO.2018.36.15_suppl.6018 |